Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization
Small · 2024
DOI: 10.1002/smll.202402141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Hong Lin Zu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China. Hauptthemen laut MEDLINE: Extracellular Matrix, Aortic Aneurysm, Abdominal, Nanomedicine, Inflammation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Plan Project.
Abstract (Originalsprache)
Abdominal aortic aneurysm (AAA) represents a critical cardiovascular condition characterized by localized dilation of the abdominal aorta, carrying a significant risk of rupture and mortality. Current treatment options are limited, necessitating novel therapeutic approaches. This study investigates the potential of a pioneering nanodrug delivery system, RAP@PFB, in mitigating AAA progression. RAP@PFB integrates pentagalloyl glucose (PGG) and rapamycin (RAP) within a metal–organic‐framework (MOF) structure through a facile assembly process, ensuring remarkable drug loading capacity and colloidal stability. The synergistic effects of PGG, a polyphenolic antioxidant, and RAP, an mTOR inhibitor, collectively regulate key players in AAA pathogenesis, such as macrophages and smooth muscle cells (SMCs). In macrophages, RAP@PFB efficiently scavenges various free radicals, suppresses inflammation, and promotes M1‐to‐M2 phenotype repolarization. In SMCs, it inhibits apoptosis and calcification, thereby stabilizing the extracellular matrix and reducing the risk of AAA rupture. Administered intravenously, RAP@PFB exhibits effective accumulation at the AAA site, demonstrating robust efficacy in reducing AAA progression through multiple mechanisms. Moreover, RAP@PFB demonstrates favorable biosafety profiles, supporting its potential translation into clinical applications for AAA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
ORCID-Profile: Hong Lin Zu
Förderung
- National Natural Science Foundation of China
- Guangzhou Science and Technology Plan Project
Zitieren
APA
Zu, H. L., Zhuang, P. P., Peng, Y., Peng, C., Peng, C., Zhu, Z. J., Yao, Y., Yue, J., Wang, Q. S., Zhou, W. H., & Wang, H. Y. (2024). Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization. Small. https://doi.org/10.1002/smll.202402141
Vancouver
Zu HL, Zhuang PP, Peng Y, Peng C, Peng C, Zhu ZJ, et al. Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization. Small. 2024. doi:10.1002/smll.202402141
BibTeX
@article{Zu2024,
author = {Zu, Hong Lin and Zhuang, Pei Pei and Peng, Ying and Peng, Chao and Peng, Cheng and Zhu, Zi Jia and Yao, Ye and Yue, Jie and Wang, Qing Shan and Zhou, Wen Hu and Wang, Hai Yang},
title = {Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202402141}
}
EUVIMED